Navigation Links
Weak spot of parasitic worms attacked to cure tropical diseases
Date:3/21/2014

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.

New funding from the Global Health Innovative Technology Fund will allow scientists from the University of Liverpool's Department of Chemistry, together with colleagues at the Liverpool School of Tropical Medicine and Japanese pharmaceutical company, Eisai, to develop new medication which is targeted at the bacteria Wolbachia.

River blindness (onchocerciasis) and elephantiasis (lymphatic filariasis) are caused by parasitic worms, and previous attempts to cure these diseases have focussed on developing drugs to kill these parasites.

Left untreated, river blindness, where the worms are transmitted by flies, can leave people robbed of their sight, whereas elephantiasis, transmitted by mosquitos, causes extreme swelling in the limbs and genitals.

However, killing the worms too suddenly can cause serious side-effects, so the research team has developed drugs which kill Wolbachia a bacteria which lives in the worms in symbiosis and without which they cannot survive.

Attacking these bacteria causes the worms to die slowly or become sterile. The team, known as the Anti-Wolbachia Consortium (A.WOL), has already shown that a four to six week course of the antibiotic, doxycycline can deplete Wolbachia from parasitic worms to cure infection, which has led to the adoption of this treatment in many areas of the world.

The new funding will allow the creation of drugs which can be used in children and pregnant women and can be effective over the course of a week.

The development of the new drugs was achieved by screening over 60,000 compounds to test their ability to kill Wolbachia. With the new funding, the most promising drug candidates will proceed through advanced rounds of chemical modification and testing to identify compounds that have a good safety and efficacy profiles, ready to move into pre-clinical testing.

Medicinal chemist, Professor Paul O'Neill from the University said: "The relationship between these worms and the bacteria is their weakness.

"By targeting the Wolbachia we can safely remove the worms and the disease, and with a quicker acting drug, we can also develop a medicine which is more useful in areas where resources are scarcer and budgets tighter."


'/>"/>

Contact: Jamie Brown
jamie.brown@liverpool.ac.uk
44-151-794-2248
University of Liverpool
Source:Eurekalert

Related biology news :

1. Europe is joining forces against neglected parasitic diseases
2. Meloidogyne mali: A new invasive plant parasitic nematode in Europe
3. Controlling parasitic worms with genetic selection
4. LSUHSC research identifies new risk factors for parasitic infection
5. Parasitic plants steal genes from their hosts
6. Marine tubeworms need nudge to transition from larvae state
7. Mating is the kiss of death for certain female worms
8. Worms and hot baths: Novel approaches to treating autism
9. Silkworms spin colored silks while on a green dyed-leaf diet
10. Microplastics make marine worms sick
11. Glowing worms illuminate the roots of behavior
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... GREENWICH, Connecticut , November 30, 2016 ...   ... Aptuit, LLC today announced ... screening library. An additional 150,000 novel compounds have increased the ... selected to broaden the hit discovery capabilities of the company. ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... technology applications, introduces the 5th generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at ... Source (LDLS™) technology, the EQ-77 offers higher radiance and irradiance from a truly ...
(Date:11/30/2016)... ... , ... With growth rates averaging more than 30% each year, Random42 has ... continuing their expansion in their new office space. The new office has a fantastic ... the creative industries, so Random42 Scientific Communication will fit right in. , Ben ...
(Date:11/30/2016)... November 30, 2016 Teil einer ... ... , Aptuit LLC ... zu haben. Zusätzliche 150.000 neuartige Substanzen haben die Prüfsammlung ... ausgewählt, um die starken Entdeckungsfähigkeiten des Unternehmens zu erweitern. ...
Breaking Biology Technology: